NEW YORK (GenomeWeb News) - Mosaic Health Care Consultants has agreed to develop reimbursement strategies and programs for Ciphergen Biosystems' ovarian cancer test, Ciphergen said yesterday.
Ciphergen's ovarian cancer triage test, which the company plans to submit for FDA approval after it completes clinical trials, uses a biomarker panel to measure risk stratification.
Ciphergen president and CEO Gail Page said in a statement that developing a reimbursement plan is for the test is "one crucial aspect of gaining rapid adoption by the medical community."
Earlier this week, the company said it had hired the consulting company Emergo to help it gain European CE Mark clearance for the test.
Ciphergen has an existing agreement with Quest Diagnostics to commercialize the biomarker-based test after FDA approval.